Physician profile
Fred E Clark
NPI 1609022086
$4,662.32
in general payments reported to CMS, 2019-2025
33 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $373 · 2021: $732 · 2022: $499 · 2023: $591 · 2024: $1,087 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.28 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.04 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $611.91 | 2020-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $493.35 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $442.31 | 2021-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $417.92 | 2019-2021 | |
| Lilly USA, LLC | $310.11 | 2021-2025 | Mounjaro, Kisunla, Zepbound |
| Astellas Pharma US INC | $213.53 | 2023-2025 | Veozah |
| Renalytix Ai, INC. | $179.56 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Pfizer INC. | $146.12 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.22 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $112.40 | 2021-2024 | Nuzyra |
| Abbott Laboratories | $93.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Vanda Pharmaceuticals INC. | $88.00 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.13 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $54.78 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $51.11 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $45.44 | 2024 | Voquezna |
| Forte Bio-Pharma LLC | $44.81 | 2025 | Prolate, Tanlor, Nalocet |
| Itamar Medical INC | $44.34 | 2025 | Watchpatone |
| Corcept Therapeutics | $39.30 | 2024 | Korlym |
| Boston Scientific Corporation | $38.53 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $34.68 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $29.43 | 2021 | |
| Coastal Medical Technologies LLC | $26.22 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.07 | 2025 | Jardiance |
| Amgen INC. | $18.23 | 2023 | Prolia, Evenity |
| Alk-Abello, INC | $17.77 | 2020 | |
| Exact Sciences Corporation | $17.71 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $16.58 | 2021 | |
| Sanofi Pasteur INC. | $15.00 | 2020 | |
| Eisai INC. | $14.02 | 2021 | |
| Radius Health, INC. | $11.79 | 2022 | |
| Merck Sharp & Dohme LLC | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.